Listing of Sygnia Itrix Solactive Healthcare 150 ETF Participatory Interests2021/07/22 10:03:00
Download PDF Stock report
Listing of Sygnia Itrix Solactive Healthcare 150 ETF Participatory Interests The Sygnia Itrix Collective Investment Scheme in Securities Sygnia Itrix Solactive Healthcare 150 ETF JSE code: SYGH Short name: SYGDMH150 ISIN code: ZAE000300521 (“SYGH”) A portfolio in the Sygnia Itrix Collective Investment Scheme in Securities, registered as such in terms of the Collective Investment Schemes Control Act, 45 of 2002. Listing of Sygnia Itrix Solactive Healthcare 150 ETF Participatory Interests The information as it appears below has been extracted from the Programme Memorandum in respect of the Sygnia Itrix Collective Investment Scheme in Securities and the Supplement relating to the Sygnia Itrix Solactive Healthcare 150 ETF and utilises the terms and definitions contained therein unless otherwise specified. 1. Introduction The JSE Limited (“JSE”) has approved the listing on the Main Board of the JSE, participatory interests in the Sygnia Itrix Solactive Healthcare 150 ETF which aims to track the Solactive Developed Markets Healthcare 150 Index and is an ETF in the Sygnia Itrix Collective Investment Scheme in Securities and shall be managed by Sygnia Itrix (RF) Proprietary Limited. 2. The Solactive Developed Markets Healthcare 150 Index The Solactive Developed Markets Healthcare 150 Index intends to track the performance of the largest 150 companies from the Healthcare Industry and is based on the Solactive Global Benchmark Series. Constituents are selected and weighted based on free float market capitalization. 3. General The Programme Memorandum and the Supplement document are available during normal business hours at the registered office of the Manager, 7th Floor, The Foundry, Cardiff Street, Green Point, Cape Town, 8001 from Thursday, 22 July 2021. The Programme Memorandum and the Supplement will also be available on the Manager’s website www.sygnia.co.za. 4. Salient dates and times SENS announcement of approval of listing Thursday, 22 July 2021 Opening date of the initial offer at 09:00 on Friday 23 July 2021 Closing date of the initial offer at 12:00 on* Monday, 26 July 2021 Letters of allocation issued Tuesday, 27 July 2021 Settlement of Letters of Allocation+ Wednesday, 28 July 2021 Publication of announcement on SENS as to the results of the initial offer: Wednesday, 28 July 2021 Ramp up period in respect of cash subscriptions commences at 09:00 on: Thursday 29 July 2021 Ramp up period in respect of cash subscriptions closes at Tuesday, 03 Aug 2021 12:00 on:** Publication of conversion ratio by 11:00 on: Wednesday, 04 Aug 2021 Listing date in respect of in specie and cash subscriptions at 09:00 on Friday, 06 Aug 2021 *Applicants should contact their broker or CSDP to ascertain the timing for submission of applications as this will vary dependent on the broker or CSDP in question. **The duration of the Ramp-Up Period may be extended depending on prevailing market liquidity, in which event the Listing Date in respect of Cash Subscriptions will occur on a later date. One letter of allotment will be issued for every Rand subscription against a subscriber’s CSDP or broker account being debited with the Rand amount. Once the Baskets of ETF Constituents have been acquired, Strate will convert the letter of allotment to Sygnia Itrix Solactive Healthcare 150 ETF participatory interests in the CSDP accounts in accordance with the conversion ratios to be published on SENS on Wednesday,4 August 2021. Sygnia Itrix Solactive Healthcare 150 ETF participatory interests will be issued in dematerialised format only. 5. The Initial Offer The initial offer is an initial public offering to investors regarding an investment in Sygnia Itrix Solactive Healthcare 150 ETF participatory interests. The initial offer is not an offer in any jurisdiction in which it is illegal to make this initial offer and in those circumstances the Programme Memorandum and Supplement are issued for information purposes only. 5.1 Conditions of the Initial Offer • Once an application has been submitted it is irrevocable and as such may not be withdrawn. • All subscriptions for Sygnia Itrix Solactive Healthcare 150 ETF participatory interests will be treated as primary market acquisitions. • All subscribers for Sygnia Itrix Solactive Healthcare 150 ETF participatory interests must have a valid account with a broking member of the JSE. Subscribers that do not have an account with a JSE member can contact any broker registered with the JSE to open an account. A list is available on the JSE website being www.jse.co.za. 5.2 Participating in the Initial Offer To participate in the initial offer for Sygnia Itrix Solactive Healthcare 150 ETF participatory interests, you must contact your JSE accredited broker. 5.3 The Issue Price of a Sygnia Itrix Solactive Healthcare 150 ETF Participatory Interest The issue price of each Sygnia Itrix Solactive Healthcare 150 ETF participatory interests will be the cost of acquiring the underlying portfolio less any applicable costs, divided by the number of participatory interests. 5.4 Discharging the Issue Price during the Initial Offer The price payable by an investor if he subscribes for securities during the period of the initial offer may be settled by a payment in cash in Rands or via an in- specie subscription. 5.5 Minimum Subscriptions The Sygnia Itrix Solactive Healthcare 150 ETF is an open-ended fund and hence there is no maximum amount regarding the Sygnia Itrix Solactive Healthcare 150 ETF participatory interests available for purchase. In respect of cash subscriptions, there is no minimum subscription amount, however an investor should be able to buy at least one Sygnia Itrix Solactive Healthcare 150 ETF participatory interest. Participatory interests will be issued in dematerialised form only. 22 July 2021 Corporate Adviser and Sponsor Vunani Sponsors Date: 22-07-2021 10:03:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.